Editorial: Incretin agonists in the treatment of obesity

Front Endocrinol (Lausanne). 2023 Aug 9:14:1265826. doi: 10.3389/fendo.2023.1265826. eCollection 2023.

Authors

Xiaodong Sun^{1

2}, Miaofen G Hu³, Lixin Li⁴

Affiliations

¹ Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
² Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
³ Department of Medicine, Division of Hematology and Oncology, Tufts Medical Center, Boston, MA, United States.
⁴ Central Michigan University, College of Health Professions, Mount Pleasant, MI, United States.

No abstract available

Keywords: Dual GIP/GLP-1R agonists; GIP; GLP-1; GLP-1R agonists; incretins; liraglutide; obesity; semaglutide.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural

MeSH terms

Humans
Incretins* / therapeutic use
Obesity* / drug therapy

Substances

Incretins

Grants and funding

UL1 TR001064/TR/NCATS NIH HHS/United States